Last reviewed · How we verify
NCT06020911
Indirect Pulp Capping Using Biodentine and Theracal Light-cured in Primary Molars
Phase 4 trial testing Biodentine in Pulp Caping in 17 participants. Completed in 1 October 2023.
1 October 2023
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 30 January 2023 |
| Primary completion | 1 October 2023 |
| Estimated completion | 1 October 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Biodentine — full drug profile →
- Theracal light cured — full drug profile →
Conditions studied
- Pulp Caping — all drugs for Pulp Caping →
- Biodentine — all drugs for Biodentine →
- Theracal — all drugs for Theracal →
Sponsor
Tanta University
Who can join
Adults 4 to 7, any sex, with Pulp Caping or Biodentine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this study is aimed to conduct tomographic evaluation of reparative dentin bridges formed after indirect pulp capping with Biodentine and Theracal light cured. The null hypothesis of the study is that there will be no difference in the quantity and quality of reparative dentin formation between the tested materials used for the indirect pulp capping
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06020911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biodentine
Trials testing the same drug.
- NCT06683833 — Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Tee · Phase 4 · recruiting
- NCT07130214 — The Effect of Genetic Polymorphisms on the Success of Vital Pulp Therapy · active not recruiting
- NCT06695208 — Socket Preservation Using Biodentin Versus Xeno Graft for Single Rooted Teeth · Phase 4 · recruiting
- NCT05937100 — New Vital Pulpotomy Medications in Primary Molars · NA · active not recruiting
- NCT07120321 — Pulpotomy Materials in Primary Molars · NA · completed
Other recruiting trials for Pulp Caping
Currently open trials in the same condition.
- NCT07130214 — The Effect of Genetic Polymorphisms on the Success of Vital Pulp Therapy · active not recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06020911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 1 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06020911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing